EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO)

Serge Ferrari, Emmanuel Biver, Elena Gonzalez-Rodriguez, Melanie Kistler-Fischbacher, Olivier Lamy, Heike Bischoff-Ferrari, Christian Meier

Swiss Medical Weekly · 2026

DOI: 10.57187/5700 ↗

At a glance

Journal article in Swiss Medical Weekly, 2026. Written by Serge Ferrari and 6 co-authors. Institution: Service des Maladies Osseuses, Department of Medicine, Geneva University Hospital (HUG) and Faculty of Medicine, Switzerland. Major MEDLINE topics: Osteoporosis, Bone Density Conservation Agents, Osteoporotic Fractures. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Osteoporosis remains a major public health burden in Switzerland and is still associated with a substantial treatment gap. These updated recommendations from the Swiss Association against Osteoporosis (SVGO) revise the 2020 risk-based framework by integrating advances in fracture-risk assessment, lifestyle management, anabolic therapy, treatment sequencing and treat-to-target concepts. Risk assessment should be based on Swiss Fracture Risk Assessment Tool (FRAX) probabilities, possibly refined by a FRAXplus approach. Five risk categories are retained – low, moderate, high, very high and imminent risk. Patients at imminent or very high risk should preferentially receive an anabolic-first strategy followed by antiresorptive consolidation. Within the anabolic class, romosozumab and abaloparatide may be preferred when the fastest and broadest bone mineral density (BMD) gain is needed, particularly at the hip. In high-risk patients, potent antiresorptives, i.e. bisphosphonates or denosumab, remain first line. In moderate-risk patients, lifestyle optimisation remains mandatory, and raloxifene or oral bisphosphonates are usually recommended, but in selected women with osteopenia or early osteoporosis, infrequent zoledronate emerges as a pragmatic preventive option. A treat-to-target concept based primarily on hip BMD is proposed, with reassessment after 2 years and treatment sequence chosen according to baseline BMD and urgency of fracture-risk reduction. These recommendations aim to improve implementation of fracture prevention in Switzerland while acknowledging reimbursement constraints and areas where evidence remains indirect.

Subjects

MeSH terms (MEDLINE)

OsteoporosisBone Density Conservation AgentsOsteoporotic FracturesHumansSwitzerlandBone DensityFemaleRisk AssessmentDiphosphonatesDenosumabRisk FactorsParathyroid Hormone-Related ProteinAntibodies, Monoclonal

Substances

Bone Density Conservation AgentsDiphosphonatesromosozumabDenosumababaloparatideParathyroid Hormone-Related ProteinAntibodies, Monoclonal

Authors and institutions

  • Service des Maladies Osseuses, Department of Medicine, Geneva University Hospital (HUG) and Faculty of Medicine, Switzerland.
  • Centre interdisciplinaire des Maladies Osseuses, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • School of Health Sciences, HES-SO Valais-Wallis, University of Applied Sciences and Arts Western Switzerland, Visp, Switzerland.
  • Department of Geriatrics, Universität Basel, Basel, Switzerland; Swiss Campus for Healthy Longevity, University of Basel, Basel, Switzerland.
  • Department Endocrinology, Diabetes and Metabolism, University Hospital Basel, University of Basel, Basel, Switzerland.

Cite

APA

Ferrari, S., Biver, E., Gonzalez-Rodriguez, E., Kistler-Fischbacher, M., Lamy, O., Bischoff-Ferrari, H., & Meier, C. (2026). Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO). Swiss Medical Weekly. https://doi.org/10.57187/5700

Vancouver

Ferrari S, Biver E, Gonzalez-Rodriguez E, Kistler-Fischbacher M, Lamy O, Bischoff-Ferrari H, et al. Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO). Swiss Medical Weekly. 2026. doi:10.57187/5700

BibTeX
@article{Ferrari2026,
  author = {Ferrari, Serge and Biver, Emmanuel and Gonzalez-Rodriguez, Elena and Kistler-Fischbacher, Melanie and Lamy, Olivier and Bischoff-Ferrari, Heike and Meier, Christian},
  title = {Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO)},
  journal = {Swiss Medical Weekly},
  year = {2026},
  doi = {10.57187/5700}
}
Start for free →